Dimethyl Fumarate — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

4 Recruiting

7 Completed trials

11 Sponsors

10 Countries

Phase III

Phase II

Phase III: 6 Phase II/III: 1 Phase II: 4 Phase I (FiH): 1

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

Indications tested

Secondary progressive multiple sclerosis 2 Relapsing-remitting multiple sclerosis 2 Friedreich's ataxia 1 Primary progressive multiple sclerosis 1 Myelofibrosis 1 Multiple sclerosis relapse 1 Multiple sclerosis 1 Progressive multiple sclerosis 1

Sponsors using this IMP

Centre Hospitalier Universitaire De Nantes 2 Antwerp University Hospital 1 Assistance Publique Hopitaux De Paris 1 AstraZeneca AB 1 Biogen Idec Research Limited 1 Celgene Corp. 1 Dipartimento Di Neuroscienze E Scienze Riproduttive Ed Odontostomatologiche Universita Degli Studi Di Napoli Federico II 1 Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL 1 Les Hopitaux Universitaires De Strasbourg 1 Medical University Of Lodz 1 Novartis Pharma AG 1

All trials

12 total

DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti… Pending

2024-513292-40-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
Long–term Analysis of DImethyl fumarate, to slow the Growth of Areas of Geographic Atrophy Recruiting

2024-510741-33-00 Phase II 1 country Assistance Publique Hopitaux De Paris
DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI… Recruiting

2024-513475-41-00 Phase III 1 country Les Hopitaux Universitaires De Strasbourg
Randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of dimethyl fumarate in brain atrophy reduction, synaptic … Recruiting

2024-517214-16-00 Phase II 1 country Medical University Of Lodz
A trial to learn if AZD0305 alone and in combination with other cancer treatments is safe and works in adults with multiple myeloma Recruiting

2023-508590-89-00 Phase I (FiH) 3 countries AstraZeneca AB
Effect of dimethyl fumarate administered to patients with adrenomyeloneuropathy: a multicenter, placebo controlled, phase IIb/III trial Ended

2023-506795-27-00 Phase II/III 1 country Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELL
Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended

2023-503190-38-00 Phase II 1 country Antwerp University Hospital
A double-blind, randomized, placebo-controlled trial to test the efficacy, safety and tolerability of Dimethyl Fumarate in Friedreich Ataxia… Ended

2022-503016-16-00 Phase II 1 country Dipartimento Di Neuroscienze E Scienze Riproduttive Ed Odontostomatologiche Univ…
STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended

2024-516628-32-00 Phase III 1 country Centre Hospitalier Universitaire De Rennes
Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n… Ended

2023-507431-37-00 Phase III 4 countries Novartis Pharma AG
A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi… Ended

2024-511972-33-00 Phase III 10 countries Celgene Corp.
Phase 3 Efficacy and Safety Study of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS). Ended

2023-505632-35-00 Phase III 1 country Biogen Idec Research Limited

Showing 1–12 of 12 trials

← All drugs A–Z